Is my fetus's growth restriction (asymmetric, abdominal circumference ~2nd percentile, estimated weight ~20th percentile at 38 weeks) likely due to genetics given a petite relative and another relative who delivered a <7‑lb infant at 42 weeks, or is it more likely caused by placental insufficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Asymmetric Fetal Growth Restriction at 38 Weeks: Genetic vs. Placental Etiology

The asymmetric pattern of growth restriction (abdominal circumference at the 2nd percentile with estimated weight at the 20th percentile) strongly suggests placental insufficiency rather than genetic or constitutional smallness, and this distinction is critical because it determines surveillance intensity and delivery timing. 1, 2

Why This Is Likely Placental Insufficiency, Not Genetic

Asymmetric Growth Pattern Is the Key Diagnostic Feature

  • Asymmetric growth restriction—where the abdominal circumference is disproportionately smaller than the head measurements—is the hallmark of placental insufficiency and late-onset fetal growth restriction (FGR). 3, 4

  • Placental dysfunction causes the fetus to preferentially preserve brain growth at the expense of liver glycogen stores and abdominal fat, resulting in a small abdominal circumference while head size remains relatively preserved. 3, 4

  • Constitutionally small fetuses (genetic smallness) typically demonstrate symmetric growth—all biometric parameters track proportionally along lower percentiles—rather than the asymmetric pattern you describe. 5

Genetic Smallness Would Present Differently

  • If this were purely genetic or constitutional smallness, you would expect all fetal measurements to track consistently along the same lower percentile throughout pregnancy, not an isolated abdominal circumference at the 2nd percentile. 5

  • The family history of a petite relative and a 7-lb infant at 42 weeks does not explain the asymmetric pattern; genetic smallness produces proportionate reduction across all measurements. 6, 5

  • Genetic factors account for approximately 30-70% of variability in birth size, but this influence manifests as symmetric smallness rather than the disproportionate abdominal growth lag seen in placental insufficiency. 6

Immediate Diagnostic Steps Required

Umbilical Artery Doppler Is Mandatory

  • You must obtain umbilical artery Doppler velocimetry immediately if not already performed—this single test differentiates pathological placental insufficiency from constitutional smallness and determines the urgency of delivery. 1, 2

  • Normal Doppler with this degree of asymmetry would be unusual and might suggest a mixed picture, but abnormal Doppler (elevated pulsatility index >95th percentile, absent or reversed end-diastolic flow) confirms placental dysfunction. 1, 2, 7

  • At 38 weeks with an abdominal circumference at the 2nd percentile, if umbilical artery Doppler shows decreased end-diastolic flow, delivery should occur immediately rather than awaiting 39 weeks. 2, 8, 7

Middle Cerebral Artery Doppler and Cerebroplacental Ratio

  • Obtain middle cerebral artery (MCA) Doppler to assess for brain-sparing physiology (increased MCA diastolic flow), which is a marker of chronic hypoxia and confirms pathological FGR. 2, 7

  • An abnormal cerebroplacental ratio (MCA-PSV/UA-PI) indicates fetal redistribution of blood flow to protect the brain and is a severity marker for placental insufficiency. 2

Amniotic Fluid Assessment

  • Measure the amniotic fluid index (AFI) or maximum vertical pocket (MVP)—oligohydramnios (AFI <5 cm or MVP <2 cm) suggests chronic placental dysfunction and significantly increases perinatal risk. 8, 7

  • The combination of asymmetric FGR with oligohydramnios at 38 weeks is an independent indication for delivery and argues strongly against expectant management. 8

Management Algorithm Based on Findings

If Umbilical Artery Doppler Is Normal

  • Proceed with delivery at 38-39 weeks as planned; induction of labor is reasonable with continuous electronic fetal monitoring throughout labor. 2, 8, 7

  • Weekly non-stress testing (cardiotocography) should continue until delivery. 7

If Umbilical Artery Doppler Shows Decreased End-Diastolic Flow

  • Deliver immediately at 38 weeks; do not delay to 39 weeks. 2, 7

  • Twice-weekly cardiotocography is required if delivery is not immediate. 7

If Absent or Reversed End-Diastolic Velocity Is Present

  • Cesarean delivery should be strongly considered, as these Doppler findings indicate severe placental insufficiency and high risk of intrapartum fetal compromise. 2, 8, 7

  • Continuous fetal monitoring during labor is mandatory if vaginal delivery is attempted, with a low threshold for cesarean section if non-reassuring patterns develop. 7

Why the Family History Does Not Override the Clinical Picture

Maternal Genetic Restraint vs. Placental Pathology

  • Maternal genetic factors that restrain fetal growth are inherited through the maternal line and are most evident in first pregnancies, but they produce symmetric smallness, not asymmetric abdominal growth restriction. 6

  • A relative delivering a <7-lb infant at 42 weeks (approximately 3,175 g at term) is within the normal range and does not establish a pattern of pathological growth restriction. 2

  • The mitochondrial DNA 16189 variant and maternally expressed genes like H19 have been associated with birth size, but these genetic influences do not cause the asymmetric pattern or the severe abdominal circumference lag you describe. 6

Placental Insufficiency Is the Most Common Cause of Late-Onset FGR

  • Uteroplacental dysfunction due to inadequate nutrient and oxygen supply is the most frequent etiology for late-onset FGR (diagnosed after 32 weeks), accounting for the majority of cases presenting at 38 weeks. 3, 9, 4

  • Deficient remodeling of uterine spiral arteries during early pregnancy leads to placental malperfusion, villous damage, and reduced surface area for maternal-fetal exchange—all of which manifest as asymmetric growth restriction. 4

  • Maternal vascular malperfusion is the most common placental disease contributing to FGR and is identifiable through Doppler studies and, if delivered, placental pathology. 9, 4

Critical Pitfalls to Avoid

  • Do not assume this is "just genetic" based on family history when the growth pattern is asymmetric—this error can lead to inadequate surveillance and delayed recognition of fetal compromise. 1, 2, 5

  • Do not delay umbilical artery Doppler assessment; it is the single most important test to distinguish pathological restriction from constitutional smallness. 1, 2, 7

  • Approximately 18-22% of fetuses with estimated weight <10th percentile are constitutionally small with normal outcomes, but an abdominal circumference at the 2nd percentile with asymmetry is not consistent with this benign category. 7

  • Avoid relying solely on estimated fetal weight percentiles—the abdominal circumference percentile and the pattern of asymmetry are equally important diagnostic criteria. 2, 7

Neonatal and Long-Term Considerations

  • All infants with FGR require evaluation in a neonatal intensive care unit due to increased risks of hypoglycemia, hypothermia, polycythemia, and respiratory distress. 7

  • Children born after FGR have increased long-term risks of neurodevelopmental delay, childhood obesity, metabolic syndrome, type 2 diabetes, hypertension, and cardiovascular disease, warranting metabolic screening in childhood and adolescence. 1, 2, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fetal Growth Restriction Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Placental insufficiency and fetal growth restriction.

Journal of obstetrics and gynaecology of India, 2011

Research

Pathophysiology of placental-derived fetal growth restriction.

American journal of obstetrics and gynecology, 2018

Research

Genetic variations and normal fetal growth.

Hormone research, 2006

Guideline

Guidelines for Detection and Management of Fetal Growth Restriction (FGR)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Intrauterine Growth Restriction at 38 Weeks with Severe Oligohydramnios

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The Placental Basis of Fetal Growth Restriction.

Obstetrics and gynecology clinics of North America, 2020

Related Questions

What causes fetal growth restriction?
At 38 weeks gestation, a fetus has asymmetric growth restriction (abdominal circumference ~2nd percentile, estimated fetal weight ~20th percentile), a normal amniotic fluid index (AFI) of 8.23, and a ductus arteriosus Doppler systolic/diastolic (S/D) ratio of 2.11; what is the recommended management?
Is a 5-centimeter placental venous lake (placental lake) at 20 weeks gestation a cause for concern?
Is a 1.8 cm placental venous lake (placental lake) on anatomy ultrasound in pregnancy a concerning finding with normal fetal anatomy and maternal vital signs?
What are the recommendations for a pregnant patient at 6 weeks 5 days gestation with a crown-rump length (CRL) of 0.48cm, fetal heart rate (FHR) of 111 beats per minute, yolk sac (YS) measuring 0.50cm, and gestational sac measuring 0.98cm, indicating a potential discrepancy in gestational age and fetal size?
Can a lumbar puncture be performed in a patient with HELLP syndrome and a platelet count of 41 × 10⁹/L?
Can bupropion, fluoxetine, and buspirone be taken together?
I’m taking Pristiq (desvenlafaxine) and started systemic steroids and now have suicidal thoughts—what should I do?
In an 80‑year‑old patient with hypertension currently taking hydralazine 12.5 mg twice daily, trandolapril 2 mg daily, and a nitroglycerin transdermal patch delivering 0.2 mg/hour, is this regimen appropriate and how should it be adjusted?
Is there an injectable ulipristal acetate (UPA) product, and what are the approved oral regimens for emergency contraception and fibroid treatment?
What is the next antihypertensive medication to add for a patient whose blood pressure rose from 145/90 mmHg to 190/100 mmHg after initiating hydrochlorothiazide 12.5 mg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.